Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5643_Библиотеки_им_академика_М_И_Перельмана.pdf
384 Herbal Pharmacopeia
FIGURE 18.8 Types of lipid- based nanocarriers.
poor solubility, low stability, and rapid elimination from the body [74]. Liposomes, solid lipid
nanoparticles, and metal nanoparticles are some of the common nanocarriers used in phytomedicine, offering unique therapeutic benets and improving patient outcomes.
18.7 CLINICAL STATUS OF CURRENT DELIVERY STRATEGIES
The clinical status of current delivery strategies for herbal medicines, particularly those incorporating nanotechnology, reects signicant progress but also faces notable challenges. Nanocarrier
systems, such as liposomes, micelles, and polymeric nanoparticles, have emerged as promising tools
in enhancing the efcacy, stability, and bioavailability of herbal compounds [75]. These advanced
delivery systems leverage their nanoscale size to improve targeted delivery, thereby reducing systemic toxicity compared to conventional administration routes. Extensive preclinical research has
demonstrated their potential, especially in treating chronic conditions like cancer and diabetes [76].
However, translating these advancements into clinical practice remains complex.
Comparative Analysis of Traditional and Nano-Formulated Approaches 385
While several nanocarrier formulations have shown promise in animal studies, only a few have
advanced to early- phase clinical trials [77]. These trials primarily focus on evaluating safety, pharmacokinetics, and initial efcacy. One signicant barrier to broader clinical adoption is the regulatory environment, which is hindered by a lack of standardized manufacturing protocols and concerns
about the long- term safety of nanomaterials [78]. The pharmaceutical industry, with its stringent
regulatory requirements, has seen slower progress in integrating nanotechnology compared to the
nutraceutical and cosmeceutical sectors, where some nano- based herbal products have already been
commercialized [79].
Emerging trends in nanomedicine, such as personalized medicine and hybrid nanocarriers, offer
promising avenues for future research and development [72]. These approaches aim to further
enhance the precision and effectiveness of drug delivery systems [57]. However, they remain in the
early experimental stages. The successful integration of nanotechnology into mainstream herbal
medicine will depend on overcoming these regulatory and safety challenges through ongoing
research and collaboration among scientists, regulators, and industry leaders [80] (Figure 18.9).
Additionally, research efforts are concentrated on improving the scalability of nanoparticle production, understanding the interactions between nanoparticles and biological systems, and optimizing delivery systems for better therapeutic outcomes. These advancements are crucial for maximizing
the potential of nanotechnology in medicine and ensuring its safe and effective use in clinical applications. Nanotechnology has revolutionized drug delivery strategies, particularly in enhancing the
FIGURE 18.9 Current trends in DDS.
386 Herbal Pharmacopeia
FIGURE 18.10 Recent advancements in drug delivery systems.
efcacy, stability, and bioavailability of herbal medicines. Preclinical studies have demonstrated the
potential of nanocarrier systems like liposomes, micelles, and polymeric nanoparticles in treating
chronic conditions such as cancer and diabetes. These nanomaterials offer advantages, such as
improved targeted delivery and reduced systemic toxicity compared to conventional drug administration routes [81].
Regulatory hurdles, such as the lack of standardization in nanoparticle manufacturing and concerns about long- term safety, have slowed the progress of nanotechnology in the pharmaceutical
sector [82]. Although some nano- herbal products have reached the market, mainly in the nutraceutical and cosmeceutical industries, the pharmaceutical sector faces stricter regulations and demands
comprehensive toxicological studies to ensure the safety of nanomaterials for human use [83]. The
demand for more effective and highly biocompatible nanomaterials continues to grow as researchers
work to overcome issues related to degradation rates and biodistribution [84] (Figure 18.10).
The rapid advancement of nanotechnology has brought about signicant improvements in drug
delivery systems, particularly in the realm of herbal medicine. Nanocarrier systems, such as liposomes,
micelles, and polymeric nanoparticles, have shown considerable promise in enhancing the efcacy,
stability, and bioavailability of herbal compounds, making them effective in treating chronic conditions like cancer and diabetes [85]. These systems leverage their nanoscale size to achieve targeted
drug delivery, which reduces systemic toxicity compared to traditional drug administration methods.
Despite these advancements, the transition from preclinical success to clinical application faces
several hurdles. Key challenges include regulatory issues stemming from the lack of standardized
manufacturing processes for nanoparticles and concerns regarding their long- term safety [86]. While
some nano- based herbal products have made it to the market, especially in the nutraceutical and
cosmetic sectors [79], the pharmaceutical industry remains cautious due to stringent regulatory
requirements. To address these issues, extensive research is ongoing to improve the biocompatibility
and effectiveness of nanomaterials, including the development of hybrid nanocarriers and personalized medicine approaches.
These innovations, although promising, are still largely in the experimental phase. The successful
integration of nanotechnology into mainstream herbal medicine will hinge on overcoming these
regulatory and safety challenges through collaborative efforts among researchers, regulators, and
industry professionals [87]. Additionally, ongoing research focuses on optimizing nanoparticle production processes for scalability and understanding the in vivo interactions between nanoparticles
and biological systems [88]. This research is crucial for maximizing the therapeutic potential of
nanotechnology and ensuring its safe and effective use in clinical settings [89].
Comparative Analysis of Traditional and Nano-Formulated Approaches 387
18.8 CONCLUSION
The integration of nanotechnology into herbal medicine represents a groundbreaking advancement
in the eld of therapeutic interventions. Traditional herbal remedies have long been celebrated for
their natural origins and therapeutic potential, yet their effectiveness has often been constrained by
issues such as poor bioavailability, high dosage requirements, and frequent administration. These
limitations have underscored the need for innovative approaches to enhance the delivery and efcacy of herbal medicines. Nano- formulated systems, leveraging cutting- edge technologies such as
liposomes, polymeric nanoparticles, and nanoemulsions, have emerged as transformative solutions
to these longstanding challenges.
The application of nanotechnology in herbal medicine offers several key advantages. Enhanced
stability and solubility of herbal bioactives, facilitated by nanocarriers, address the issues of poor
absorption and rapid clearance that have historically impeded the therapeutic potential of traditional
formulations. Through improved bioavailability and targeted delivery, nano- formulations not only
increase the efcacy of herbal treatments but also reduce the frequency of dosing and minimize side
effects. This rened approach to drug delivery exemplies the promise of nanotechnology in bridging the gap between conventional herbal practices and modern therapeutic needs.
Despite the considerable benets, the transition to nano- formulated herbal products is not without its challenges. Rigorous research and development are essential to ensure the safety, efcacy,
and regulatory compliance of these advanced formulations. The complexity of manufacturing processes and the need for comprehensive safety evaluations present signicant hurdles that must be
addressed to facilitate the widespread adoption of nano- formulated herbal medicines. Moreover,
regulatory frameworks need to evolve to accommodate these novel delivery systems, ensuring that
they meet the necessary standards for quality and safety.
Ongoing research and development efforts are crucial for realizing the full potential of nanoformulated herbal medicines. Continued exploration into their mechanisms of action, therapeutic
advantages, and long- term effects will provide deeper insights into how these advanced systems can
be optimized for clinical use. As the eld advances, collaborative efforts between researchers, regulatory bodies, and industry stakeholders will be essential in addressing the challenges and maximizing the benets of these innovative therapies.
In conclusion, the intersection of nanotechnology and herbal medicine holds signicant promise
for the future of healthcare. By overcoming the limitations of traditional herbal formulations and
enhancing therapeutic efcacy through advanced delivery systems, nano- formulated herbal medicines represent a valuable evolution in the eld. As research progresses and regulatory pathways are
established, these innovations have the potential to transform herbal medicine, offering more effective, targeted, and patient- friendly treatments. The continued exploration and development of nanoformulated herbal products will undoubtedly contribute to advancing therapeutic practices and
improving patient outcomes in the years to come.
REFERENCES
1. Liu, H., Y. Bai, C. Huang, Y. Wang, Y. Ji, Y. Du, et al. “Recent Progress of Electrospun Herbal Medicine
Nanobers.” Biomolecules, 2023. Available from: https:// www. mdpi. com/ 2218- 273X/ 13/ 1/ 184. Accessed
September 12, 2024.
2. Doench, J. G., N. Fusi, M. Sullender, M. Hegde, E. W. Vaimberg, K. F. Donovan, I. Smith, and Z.
Tothova. 2016. “Optimized sgRNA Design to Maximize Activity and Minimize Off- Target Effects of
CRISPR- Cas9.” Nature Biotechnology. Accessed September 12, 2024. Available from https:// www.
nature. com/ articles/ nbt. 3437
3. Bhalani, D., B. Nutan, and A. Kumar. 2022. “Bioavailability Enhancement Techniques for Poorly
Aqueous Soluble Drugs and Therapeutics.” Biomedicines. Accessed September 12, 2024. https:// www.
mdpi. com/ 2227- 9059/ 10/ 9/ 2055
388 Herbal Pharmacopeia
4. Viegas, C., A. B. Patrício, J. M. Prata, A. Nadhman, P. K. Chintamaneni, and P. Fonte. 2023. “Solid Lipid
Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review.” Pharmaceutics. Accessed
September 12, 2024. Available From: https:// www. mdpi. com/ 1999- 4923/ 15/ 6/ 1593
5. Horcajada, P., T. Chalati, C. Serre, B. Gillet, C. Sebrie, T. Baati, J. F. Eubank, and D. Heurtaux. 2010.
“Porous Metal–Organic- Framework Nanoscale Carriers as a Potential Platform for Drug Delivery and
Imaging.” Nature Materials. Accessed September 12, 2024. Available from: https:// www. nature. com/
articles/ nmat2608
6. Haseli, S., M. Pourmadadi, A. Samadi, F. Yazdian, M. Abdouss, H. Rashedi, et al. 2022. “A Novel
pH- Responsive Nanoniosomal Emulsion for Sustained Release of Curcumin from a Chitosan- Based
Nanocarrier: Emphasis on the Concurrent Improvement of Loading, Sustained Release, and Apoptosis
Induction.” Biotechnology Progress 38 (5): e3280.
7. Zhang, M., X. Wang, C. Wei, M. Wang, W. Han, Z. Yuan, et al. 2023. “Effects of Exogenous Phosphates
on Speciation and Bioavailability of Arsenic and Cadmium in Farmland Soils.” Journal of Soils and
Sediments 23 (4): 1832–43.
8. Lee, H. G., M. A. Wheeler, and F. J. Quintana. 2022. “Function and Therapeutic Value of Astrocytes in
Neurological Diseases.” Nature Reviews Drug Discovery. Accessed September 12, 2024. Available from:
https:// www. nature. com/ articles/ s41573- 022- 00390- x
9. Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, and G. Pérez
Marc. 2020. “Safety and Efcacy of the BNT162b2 mRNA Covid- 19 Vaccine.” New England Journal of
Medicine 383 (27): 2603–15. Accessed September 12, 2024. Available from: https:// www. nejm. org/ doi/
full/ 10. 1056/ nejmoa2034577
10. Kumar, R., P. Saha, P. Lokare, K. Datta, P. Selvakumar, and A. Chourasia. 2022. “A Systemic Review
of Ocimum Sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic
Applications.” International Journal for Research in Applied Sciences and Biotechnology. Accessed
September 12, 2024. Available from https:// ijrasb. com/ index. php/ ijrasb/ article/ view/ 251
11. Marso, S. P., Daniels, G. H., Brown- Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., … & Buse,
J. B. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, Drug and Therapeutics Bulletin
54 (9): 101.
12. John, A., H. H. Yang, S. Muhammad, Z. I. Khan, H. Yu, M. Luqman, M. Tofail, and M. I. Hussain. 2022.
“Cross Talk Between Synthetic Food Colors (Azo Dyes), Oral Flora, and Cardiovascular Disorders.”
Applied Sciences. Accessed September 12, 2024. https:// www. mdpi. com/ 2076- 3417/ 12/ 14/ 7084.
13. Bray, F., J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal. 2018. “Global Cancer
Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
Countries.” CA: A Cancer Journal for Clinicians 68 (6): 394–424. Accessed September 12, 2024. https://
acsjournals. onlinelibrary. wiley. com/ doi/ abs/ 10. 3322/ CAAC. 21492
14. Bhimraj, A., R. L. Morgan, A. H. Shumaker, L. R. Baden, V. C. C. Cheng, K. M. Edwards, J. C. Gallagher,
et al. 2024. “Infectious Diseases Society of America Guidelines on the Treatment and Management of
Patients with COVID- 19 (September 2022).” Clinical Infectious Diseases. Accessed September 12,
2024. https:// academic. oup. com/ cid/ article- abstract/ 78/ 7/ e250/ 6692369
15. Wilson, D. M., M. R. Cookson, L. Van Den Bosch, H. Zetterberg, D. M. Holtzman, and I. Dewachter.
2023. “Hallmarks of Neurodegenerative Diseases.” Cell. Accessed September 12, 2024. https:// www.
cell. com/ cell/ fulltext/ S0092- 8674( 22) 01575-6.
16. Al- Khayri, J. M., G. R. Sahana, P. Nagella, B. V. Joseph, F. Alessa, and M. Al- Mssallem. 2022.
“Flavonoids as Potential Anti- Inammatory Molecules: A Review.” Molecules 27. Accessed September
12, 2024. https://doi.org/10.3390/molecules27092901
17. Saini, R., A. Ranjit, K. Sharma, P. Prasad, X. Shang, K. G. M. Gowda, and Y. S. Keum. 2022. “Bioactive
Compounds of Citrus Fruits: A Review of Composition and Health Benets of Carotenoids, Flavonoids,
Limonoids, and Terpenes.” Antioxidants 11 (2): 239. Accessed September 12, 2024. https://www.mdpi.
com/2076-3921/11/2/239
18. Bureau, J., M. E. Oliva, Y. Dong, and C. Ignea. 2023. “Engineering Yeast for the Production of Plant
Terpenoids Using Synthetic Biology Approaches.” Natural Product Reports. Accessed September 12,
2024. https://pubs.rsc.org/en/content/articlehtml/2023/np/d3np00005b
19. Dhyani, P., C. Quispe, E. Sharma, A. Bahukhandi, P. Sati, D. C. Attri, et al. 2022. “Anticancer Potential of
Alkaloids: A Key Emphasis to Colchicine, Vinblastine, Vincristine, Vindesine, Vinorelbine and Vincamine.”
Cancer Cell International 22(1). Available from https://doi.org/10.1186/s12935-022-02153-4
Comparative Analysis of Traditional and Nano-Formulated Approaches 389
20. Uroševic, M., L. Nikolic, I. Gajic, V. Nikolic, A. Dinic, and V. Miljkovic. 2022. “Curcumin: Biological
Activities and Modern Pharmaceutical Forms.” Antibiotics 11(2): 135. Accessed September 12, 2024.
https://www.mdpi.com/2079-6382/11/2/135
21. Meng, T., D. Xiao, A. Muhammed, J. Deng, L. Chen, J. He. 2021. “Anti- Inammatory Action and
Mechanisms of Resveratrol.” Molecules 26(1): 229. Accessed September 12, 2024. https://www.mdpi.
com/1420-3049/26/1/229
22. Dutt, Y., R. P. Pandey, M. Dutt, A. Gupta, A. Vibhuti, V. S. Raj, C. M. Chang, and A. Priyadarshini.
2023. “Liposomes and Phytosomes: Nanocarrier Systems and Their Applications for the Delivery of
Phytoconstituents.” Coordination Chemistry Reviews. Accessed September 12, 2024. https://www.
sciencedirect.com/science/article/pii/S0010854523002400
23. Djahra, A. B., I. Lmhanat, M. Benkaddour, S. Benkherara, I. Laib, and C. Benine. 2023. “Traditional
Herbal Remedies from Algeria for Treating Digestive Disorders.” Journal of Drug Delivery and
Therapeutics 13(1): 1–10. Accessed September 12, 2024. http://www.jddtonline.info/index.php/jddt/
article/view/5906
24. Kumar, R., P. Saha, P. Lokare, K. Datta, P. Selvakumar, and A. Chourasia. 2022. “A Systemic Review of
Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications.”
International Journal for Research in Applied Sciences and Biotechnology. Accessed September 12, 2024.
https://ijrasb.com/index.php/ijrasb/article/view/251
25. Hashem, A., A. M. Abdelaziz, A. A. Askar, H. M. Fouda, A. M. A. Khalil, K. A. Abd- Elsalam, and
M. M. Khaleil. 2021. “Bacillus megaterium- Mediated Synthesis of Selenium Nanoparticles and Their
Antifungal Activity Against Rhizoctonia solani in Faba Bean Plants.” Journal of Fungi 7 (3): 195.
Accessed September 12, 2024. https://www.mdpi.com/2309-608X/7/3/195
26. Burstein, O., A. Shamir, N. Abramovitz, and R. Doron. 2022. “Patients’ Attitudes Toward Conventional
and Herbal Treatments for Depression and Anxiety: A Cross- Sectional Israeli Survey.” International
Journal of Social Psychiatry 2022 (3): 589–99. Accessed September 12, 2024. https://journals.sagepub.
com/doi/abs/10.1177/0020764021992385
27. Claus- Desbonnet, H., E. Nikly, V. Nalbantova, D. Karcheva- Bahchevanska, S. Ivanova, and G. Pierre.
2022. “Polysaccharides and Their Derivatives as Potential Antiviral Molecules.” Viruses 14 (2): 426.
Accessed September 12, 2024. https://www.mdpi.com/1999-4915/14/2/426.
28. Rezaei- Tazangi, F., H. Roghani- Shahraki, M. Khorsand Ghaffari, and F. Abolhasani Zadeh. 2021. “The
Therapeutic Potential of Common Herbal and Nano- Based Herbal Formulations Against Ovarian Cancer:
New Insight into the Current Evidence.” Pharmaceuticals 14 (12): 1315. Accessed September 12, 2024.
Available from: https://www.mdpi.com/1424-8247/14/12/1315.
29. Portney, L., and M. Watkins. 2009. Foundations of Clinical Research: Applications to Practice.
Accessed September 12, 2024. Available from : https://babymariam.gm/sites/default/les/webform/pdffoundations- of- clinical- research- applications- to- practice- 3rd- e- leslie- g- portney- mary- p- watkins- pdfdownload- free- book- d3094a3.pdf
30. Di Lorenzo, C., F. Colombo, S. Biella, C. Stockley, and P. Restani. 2021. “Polyphenols and Human Health:
The Role of Bioavailability.” Nutrients 13: 273. Available from: https://doi.org/10.3390/nu13010273
31. Iordache, T., N. Badea, M. Mihaila, S. Crisan, A. L. Pop, and I. Lacatusu. 2021. “Challenges in Coopted
Hydrophilic and Lipophilic Herbal Bioactives in the Same Nanostructured Carriers for Effective
Bioavailability and Anti- Inammatory Action.” Nanomaterials 11 (11): 3035. Accessed September 12,
2024. https://www.mdpi.com/2079-4991/11/11/3035.
32. Marsden, A., and A. Shahtout. 2024. “International Organization for Standardization.” Clinical
Laboratory Management. Wiley Online Library. Accessed September 12, 2024. Available from: https://
onlinelibrary.wiley.com/doi/abs/10.1002/9781683673941.ch19.
33. Hesarzadeh, R., A. Bazrafshan, and S. Aqel. 2022. “Audit Committee and Regulatory Scrutiny.” Revista
de Administração de Empresas. SciELO Brasil. Accessed September 12, 2024. https://doi.org/10.1590/
S0034-759020220603.
34. Westlake, S., C.H.D. John, and E. Cox. 2023. “Perception Spillover from Fracking onto Public Perceptions
of Novel Energy Technologies.” Nature Energy. Accessed September 12, 2024. https://www.nature.com/
articles/s41560-022-01178-4
35. Kumar, A., P. Nirmal, M. Kumar, A. Jose, V. Tomer, E. Oz, C. Proestos, M. Zeng, T. Elobeid, K. Sneha,
and F. Oz. 2023. “Major Phytochemicals: Recent Advances in Health Benets and Extraction Method.”
Molecules. Accessed September 12, 2024. https://www.mdpi.com/1420-3049/28/2/887
390 Herbal Pharmacopeia
36. Townsend, B.A., I. Sihlahla, M. Naidoo, S. Naidoo, D.L. Donnelly, and D.W. Thaldar. 2023. “Mapping
the Regulatory Landscape of AI in Healthcare in Africa.” Frontiers in Pharmacology 14: 1214422.
37. Li, W., J.Y. Chen, R.N. Terry, J. Tang, A. Romanyuk, S.P. Schwendeman, and M.R. Prausnitz. 2022.
“Core- Shell Microneedle Patch for Six- Month Controlled- Release Contraceptive Delivery.” Journal of
Controlled Release. Elsevier. Accessed September 12, 2024. Available from https://www.sciencedirect.
com/science/article/pii/S0168365922002656
38. Lai, S., Z. Chen, Y. Zhang, G. Li, Y. Wang, and Q. Cui. 2022. “Micronization Effects on Structural,
Functional, and Antioxidant Properties of Wheat Bran.” Foods. MDPI. Accessed September 12, 2024.
https://www.mdpi.com/2304-8158/12/1/98
39. Narade, S. B., and Y. V. Pore. 2023. “Pharmacokinetic Assessment of Natural Anticancer Berberine
Chloride in Presence and Absence of Some Herbal Bioenhancers in Rabbit Model.” Research Journal of
Pharmacy and Technology 16 (11): 5121–29. https://doi.org/10.52711/0974-360X.2023.00830
40. Smith, P. M., M. R. Howitt, N. Panikov, M. Michaud, C. A. Gallini, M. Bohlooly- Y, et al. 2013. “The
Microbial Metabolites, Short- Chain Fatty Acids, Regulate Colonic T Reg Cell Homeostasis.” Science
341 (6145): 569–73.
41. Badmus, S. O., H. K. Amusa, T. A. Oyehan, and T. A. Saleh. 2021. “Environmental Risks and Toxicity of
Surfactants: Overview of Analysis, Assessment, and Remediation Techniques.” Environmental Science
and Pollution Research 28 (44): 62085–104.
42. Kumar, A., P. K. Naik, D. Pradhan, G. Ghosh, and G. Rath. 2020. “Mucoadhesive Formulations:
Innovations, Merits, Drawbacks, and Future Outlook.” Pharmaceutical Development and Technology
25 (7): 797–814.
43. Yu, Z., J. P. Huang, J. Yang, C. Liu, Y. Yan, L. Wang, J. Zhao, Y. Chen, W. Xiang, and S. X. Huang. 2023.
“Discovery and Biosynthesis of Karnamicins as Angiotensin Converting Enzyme Inhibitors.” Nature
Communications. Available from: https://doi.org/10.1038/s41467-023-35829-1
44. Pérez- Sánchez, A., Cuyàs, E., Ruiz- Torres, V., Agulló-Chazarra, L., and Verdura, S. “Intestinal Permeability
Study of Clinically Relevant Formulations of Silibinin in Caco- 2 Cell Monolayers.” International Journal
of Molecular Sciences, 2019. Available from: https://doi.org/10.3390/ijms20071606
45. Kagathara, C., K. Odedra, and N. Vadia. 2022. “Development of HPTLC Method for the Simultaneous
Estimation of Quercetin, Curcumin, and Ascorbic Acid in Herbal Formulations.” Journal of the Iranian
Chemical Society 19 (3): 4129–38. https://doi.org/10.1007/s13738-022-02586-9
46. Sabour, S., N. Frosst, and G. E. Hinton. 2017. “Dynamic Routing Between Capsules.” Advances in
Neural Information Processing Systems. Available from https://proceedings.neurips.cc/paper_les/
paper/2017/hash/2cad8fa47bbef282badbb8de5374b894-Abstract.html
47. Baishya, H. (2017). Application of Mathematical Models in Drug Release Kinetics of Carbidopa and
Levodopa ER Tablets. Journal of Developing Drugs. 06. 10.4172/2329-6631.1000171.
48. Yu, Y., G. Wang, X. Yin, C. Ge, and G. Liao. 2021. “Effects of Different Cooking Methods on Free Fatty
Acid Prole, Water- Soluble Compounds and Flavor Compounds in Chinese Piao Chicken Meat.” Food
Research International. https://www.sciencedirect.com/science/article/pii/S0963996921005950
49. Vazquez- Quintal, Patricia, Jesús Barrón- Zambrano, Salvador Medina- Peralta, Yolanda Moguel- Ordoñez,
Jenny Nelson, and David Muñoz- Rodríguez. 2023. “Elemental Analysis of Propolis Tinctures by
Microwave Plasma–Atomic Emission Spectrometry (MP- AES).” Analytical Letters 56 (14): 2249–2261.
https://doi.org/10.1080/00032719.2022.2163401
50. Martinello, M., R. Stella, A. Baggio, G. Biancotto, and F. Mutinelli. 2022. “LC- HRMS- Based Non-
Targeted Metabolomics for the Assessment of Honey Adulteration with Sugar Syrups: A Preliminary
Study.” Metabolites 12 (10): 985. https://doi.org/10.3390/metabo12100985
51. Amorati, R., Foti, M. C., and Valgimigli, L. 2013. “Antioxidant Activity of Essential Oils.” Journal of
Agricultural and Food Chemistry 61 (46): 10835–47. https://doi.org/10.1021/jf402634r
52. Blauvelt, A., Kempers, S., Lain, E., Schlesinger, T., Tyring, S., Forman, S., et al. 2021. “Phase 3 Trials of
Tirbanibulin Ointment for Actinic Keratosis.” New England Journal of Medicine 384 (6): 512–20. https://
doi.org/10.1056/NEJMoa2028912
53. Mansour, M. M. A., and M. Z. M. Salem. 2023. “Poultices as Biolms of Titanium Dioxide Nanoparticles/
Carboxymethyl Cellulose/Phytagel for Cleaning of Infected Cotton Paper by Aspergillus sydowii
and Nevskia terrae.” Environmental Science and Pollution Research 30 (53): 114625–45. https://doi.
org/10.1007/s11356-023-27814-x
Comparative Analysis of Traditional and Nano-Formulated Approaches 391
54. Wang, S., X. Xiao, A. Li, and P. Li. 2021. “The Herbal Constituents in An- Gong- Niu- Huang Wan
(AGNH) Protect Against Cinnabar- and Realgar- Induced Hepatorenal Toxicity and Accumulations of
Mercury and Arsenic in Mice.” Evidence- Based Complementary and Alternative Medicine 2021: 1–10.
https://doi.org/10.1155/2021/5538765
55. Jiang, J., X. Ma, D. Ouyang, and R. O. Williams III. 2022. “Emerging Articial Intelligence (AI)
Technologies Used in the Development of Solid Dosage Forms.” Pharmaceutics 14 (11): 2257. https://
doi.org/10.3390/pharmaceutics14112257
56. Sharma, R., P. Bedarkar, D. Timalsina, A. Chaudhary, and P. K. Prajapati. 2022. “Bhavana, an Ayurvedic
Pharmaceutical Method and a Versatile Drug Delivery Platform to Prepare Potentiated Micro- NanoSized Drugs: Core Concept and Its Current Relevance.” Bioinorganic Chemistry and Applications 2022:
Article ID 5580731. https://doi.org/10.1155/20225580731
57. Yusuf, A., A. R. Z. Almotairy, H. Henidi, O. Y. Alshehri, and M. S. Aldughaim. 2023. “Nanoparticles as
Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on
Responses in Biological Systems.” Polymers 15 (7): 1596. https://doi.org/10.3390/polym15071596
58. Li, R., Y. Pan, D. Chen, X. Xu, G. Yan, and T. Fan. 2022. “Design, Preparation and In Vitro Evaluation
of Core- Shell Fused Deposition Modelling 3D- Printed Verapamil Hydrochloride Pulsatile Tablets.”
Pharmaceutics 14 (2): 437. Available from: https://doi.org/10.3390/pharmaceutics14020437
59. Chen, Y., D. Li, N. Li, P. Y. Loh, Y. Guo, X. Hu, et al. 2023. “Role of Nerve Signal Transduction and
Neuroimmune Crosstalk in Mediating the Analgesic Effects of Acupuncture for Neuropathic Pain.”
Frontiers in Neurology 14 (January 23). https://doi.org/10.3389/fneur.2023.1002423
60. Jayaprakash, A.A., P.R. Aswin, and S.R. Rathinam. April 2022. “Joint Pain Liniments and Gum Lotion
in the Eye—A Consecutive Case Series of Mistaken Identity.” Indian Journal of Ophthalmology 70 (4):
1159–1162. https://doi.org/10.4103/ijo.IJO_2328_21
61. Dubey, S.K., Parab, S., Achalla, V.P.K., Narwaria, A., Sharma, S., Jaswanth Gowda, B.H., et al. 2022.
“Microparticulate and Nanotechnology Mediated Drug Delivery System for the Delivery of Herbal
Extracts.” Journal of Biomaterials Science, Polymer Edition 33 (12): 1531–1554.
62. Paunovska, K., Loughrey, D. & Dahlman, J.E. 2022. Drug delivery systems for RNA therapeutics. Nature
Reviews Genetics 23, 265–280.Available form: https://doi.org/10.1038/s41576-021-00439-4
63. Yang, Yang, Gang Xiao, Pengcheng Cheng, Jing Zeng, and Yun Liu. 2023. “Protective Application
of Chinese Herbal Compounds and Formulae in Intestinal Inammation in Humans and Animals.”
Molecules 28. Accessed September 12, 2024. https://www.mdpi.com/1420-3049/28/19/6811
64. Wang, Shu, Yuhua Chen, Jian Guo, and Qian Huang. 2023. “Liposomes for Tumor Targeted Therapy:
A Review.” International Journal of Molecular Sciences 24 (3). Accessed September 12, 2024. https://
www.mdpi.com/1422-0067/24/3/2643
65. Khan, Imran, and Khalid Saeed. 2019. “Nanoparticles: Properties, Applications and Toxicities.”
International Journal of Chemical Sciences 24 (3). Accessed September 12, 2024. https://www.science
direct.com/science/article/pii/S1878535217300990
66. Giuili, Elsa, Renaud Grolaux, Carla Z.N.M. Macedo, Laurence Desmyter, Benjamin Pichon, Sophie
Neuens, et al. 2023. “Comprehensive Evaluation of the Implementation of Episignatures for Diagnosis
of Neurodevelopmental Disorders (NDDs).” Human Genetics 142 (12): 1721–35.
67. Booth, Amy, Alexandra Jager, Stuart D. Faulkner, Christopher C. Winchester, and Sara E. Shaw. 2023.
“Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of
Public Reports from 20 Pharmaceutical Companies.” International Journal of Environmental Research
and Public Health 20 (4). Accessed September 12, 2024. https://doi.org/10.3390/ijerph20043206
68. Newman, David J., and Gordon M. Cragg. 2016. “Natural Products as Sources of New Drugs from 1981
to 2014.” Journal of Natural Products 79, (3): 629–61. https://doi.org/10.1021/acs.jnatprod.5b01055
69. Abbasi, R., G. Shineh, M. Mobaraki, S. Doughty, and L. Tayebi. 2023. “Structural Parameters of
Nanoparticles Affecting Their Toxicity for Biomedical Applications: A Review.” Journal of Nanoparticle
Research 25 (3). https://doi.org/10.1007/s11041-023-01592-2
70. Mitchell, M.J., M.M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer 2021.
Engineering Precision Nanoparticles for Drug Delivery. Nature Reviews Drug Discovery. Accessed
September 12, 2024. Available from: https://www.nature.com/articles/s41573-020-0090-8
71. Mura, S., J. Nicolas, and P. Couvreur 2013. Stimuli- responsive Nanocarriers for Drug Delivery. Nature
Materials. Accessed September 12, 2024. Available from: https://www.nature.com/articles/nmat3776
392 Herbal Pharmacopeia
72. Shi, J., P. W. Kantoff, R. Wooster, and O. C. Farokhzad 2017. Cancer Nanomedicine: Progress, Challenges,
and Opportunities. Nature Reviews Cancer. Accessed September 12, 2024. Available from: https://www.
nature.com/articles/nrc.2016.108
73. Pulipaka, S., M. R. Kumar, P. Sriram, and A. Suttee 2021. A Review On Nano Drug Delivery Systems of
Herbal Medicine. Journal of Emerging Technologies and Innovative Research Accessed September 12,
2024. Available from: https://www.academia.edu/download/83411255/JETIR2102189.pdf
74. Lombardo, D., and M. A. Kiselev 2022. Methods of Liposomes Preparation: Formation and Control
Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. Pharmaceutics.
Accessed September 12, 2024. Available from: https://www.mdpi.com/1999-4923/14/3/543
75. Chavda, V. P., L. V. Nalla, P. Balar, R. Bezbaruah, V. Apostolopoulos, R. K. Singla, A. Khadela 2023.
Advanced Phytochemical- based Nanocarrier Systems for the Treatment of Breast Cancer. Cancers.
Accessed September 12, 2024. Available from: https://www.mdpi.com/2072-6694/15/4/1023
76. Makarova, M. N., and V. G. Makarov. 2023. Dogs in Preclinical Research. Laboratornye Zhivotnye dlya
nauchnych issledovanii (Laboratory Animals for Science) 6 (4): 26.
77. Negi, P., A. Singh, S. Pundir, A. Parashar, N. Upadhyay, S. Agarwal, et al. 2023. Essential Oil and
Nanocarrier- based Formulations Approach for Vaginal Candidiasis. Therapeutic Delivery 14 (3): 207–25.
78. Bird, R., Z. J. Baum, X. Yu, and J. Ma 2022. The regulatory environment for lithium- ion battery recy-
cling. ACS Energy Letters Journal 7 (2): 736–40.
79. Pouryouse-Koodehi, T., M. S. Kahrizi, H. Roghani- Shahraki, F. Rezaei- Tazangi, and R. Arefnezhad
2024. Nano- based herbal medicine: A new candidate for prostate cancer treatment? Current Traditional
Medicine. Accessed September 12, 2024. Available from: https://www.ingentaconnect.com/content/ben/
ctm/2024/00000010/00000007/art00018
80. Leskovac, A., and S. Petrovic 2023. Pesticide Use and Degradation Strategies: Food Safety, Challenges,
and Perspectives. Foods. Accessed September 12, 2024. Available from: https://www.mdpi.com/2304-
8158/12/14/2709
81. Ru, J., P. Li, J. Wang, W. Zhou, B. Li, C. Huang, et al. 2014. TCMSP: A Database of Systems Pharmacology
for Drug Discovery From Herbal Medicines. Journal of Cheminformatics 6 (1). Accessed September 12,
2024. Available from: https://link.springer.com/article/10.1186/1758-2946-6-13
82. Shepherd, S.J., X. Han, A. J. Mukalel, R. El- Mayta, A.S. Thatte, J. Wu, et al. 2023 Throughput- scalable
Manufacturing of SARS- CoV- 2 mRNA Lipid Nanoparticle Vaccines. Proceedings of the National
Academy of Sciences of the United States of America 33: e2303567120.
83. Augustyniak, J., A. Bertero, T. Coccini, D. Baderna, L. Buzanska, F. Caloni. 2019 Dec 1. Organoids are
Promising Tools for Species- specic in Vitro Toxicological Studies. Journal of Applied Toxicology. 39
(12): 1610–22.
84. Handa, M., S. K. Maharana, K. Pal, and R. Shukla 2022. Biocompatible Nanomaterials for Burns.
Current Pharmaceutical Biotechnology. Accessed September 12, 2024. Available from: https://www.
ingentaconnect.com/content/ben/cpb/2022/00000023/00000012/art00010
85. Rakotondrabe, T., M. Fan, F. Muema, M. Ghosh 2023. Modulating inammation- Mediated Diseases via
Natural Phenolic Compounds Loaded in Nanocarrier Systems. Pharmaceutics. Accessed September 12,
2024. Available from: https://www.mdpi.com/1999-4923/15/2/699
86. Harris, A.R., M.J. Walker, and F. Gilbert 2022. Ethical and Regulatory Issues of Stem Cell- derived
3-Dimensional Organoid and Tissue Therapy for Personalized Regenerative Medicine. BMC Med 20(1).
87. Malik, S., K. Muhammad, and Y. Waheed (2023) Nanotechnology: A Revolution in Modern Industry.
Molecules. Accessed September 12, 2024. Available from: https://www.mdpi.com/1420-3049/28/2/661
88. Palmieri, V., G. Perini, M. De Spirito, and M. Papi (2019) Graphene Oxide Touches Blood: In Vivo
Interactions of Bio- coronated 2D Materials. Nanoscale Horizons. Accessed September 12, 2024.
Available from: https://pubs.rsc.org/en/content/articlehtml/2018/nh/c8nh00318a
89. Slika, H., Mansour, H., Wehbe, N., Nasser, S.A., Iratni, R., Nasrallah, G., Shaito, A., and Ghaddar, T.
2022. “Therapeutic Potential of Flavonoids in Cancer: ROS- Mediated Mechanisms.” Biomedicine &
Pharmacotherapy. Elsevier. Available from: https://www.sciencedirect.com/science/article/pii/S0753332
221012282
Implementing Herbal
19
Nanomedicine in Clinical
Settings with Patient Care
Histories Treatment Protocols
and Observed Benets
Saleem Ur Rahman, Asma Zahoor, Mashaal Nageen,
Afsheen Tajummal, Ehtisham Shaque, Nasir Ali,
and Farakh Javed
Department of Biological and Health Sciences, Pak-Austria Fachhochschule:
Institute of Applied Sciences and Technology, Haripur, Pakistan
19.1 INTRODUCTION
The year 1999 saw the emergence of nanomedicines, while herbal nanomedicine is a new branch
that combines nano science principles with traditional herbal medicine. This process involves the
manipulation of materials at the nanoscale (typically 1 to 100 nm) with unique physical and chemical properties, thereby enabling the fabrication of novel therapeutic agents [1]. In herbal nanomedicine, bioactive compounds from plants are designed as nanoparticles to improve their delivery,
activity, and safety in the treatment of different medical conditions.
19.1.1 Definition anD Scope
Herbal medicines have been increasingly used across the world for diseases due to their superior
characteristics to other synthetic drugs, which are more toxic in nature. A considerable number of
infections and life- threatening diseases can be treated by various useful and medicinal plants, providing vital resources for modern pharmaceutical industries. Over a long period, researchers have
investigated the activities related to the uses of herbs as therapeutics and it has been found out that
such drugs are environmentally friendly, in contrast to their counterparts, which are synthesized
because they possess low stability, solubility, and problem with bioavailability [2].
Nanotechnology is a groundbreaking eld that has managed to address many challenges related
to herbal medicine through its widespread effectiveness in diverse situations with no side effects.
For instance, over the past few decades Ayurvedic herbs have exhibited strong activity against various chronic diseases such as asthma [3], cancer [4], diabetes [5], heart diseases [6], and multiple
sclerosis [7]. These are the most in- demand products on the market having therapeutic properties
such as being anticancer, antioxidant, and gene protecting, all of which can challenge the upcoming
problems for the pharma industries.
Nanotechnology is one of the main scientic branches, and includes physics, chemistry, biology,
and computer science. In this eld, structures and components are studied within the 1 to 100 nm
393